Literature DB >> 15833928

CYP3A5 genetic polymorphisms in different ethnic populations.

Jean-Nicholas Roy1, Julie Lajoie, Lynn S Zijenah, Azemi Barama, Charles Poirier, Brian J Ward, Michel Roger.   

Abstract

Cyp3A5 activity varies within any given ethnic population, suggesting that genetic variation within the Cyp3A5 gene may be the most important contributor to interindividual and interracial differences in Cyp3A-dependent drug clearance and response. The full extent of Cyp3A5 polymorphism in a white and an indigenous African population was analyzed using DNA direct sequencing procedures. The presence of 10 and 12 single nucleotide polymorphisms was detected in the white and African samples, respectively. Thirteen novel mutations occurring at low frequencies were identified in these populations. Significant differences were observed in the distribution of Cyp3A5*3, Cyp3A5*6, and Cyp3A5*7 alleles among white and African populations. The frequency of Cyp3A5*3 allele in white Canadians (approximately 93%) is higher than in Zimbabweans (77.6%) (p < 0.001). In contrast, Cyp3A5*6 and Cyp3A5*7 alleles are relatively frequent in African subjects (10-22%) but absent in white subjects (p < 0.001). These differences may reflect evolutionary pressures generated by environmental factors in geographically distinct regions. However, the genetic polymorphism of Cyp3A5 alone does not explain the interindividual differences in Cyp3A-mediated metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833928     DOI: 10.1124/dmd.105.003822

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  45 in total

1.  Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.

Authors:  Jiraphun Jittikoon; Surakameth Mahasirimongkol; Angkana Charoenyingwattana; Usa Chaikledkaew; Pramote Tragulpiankit; Supachoke Mangmool; Wimala Inunchot; Chayapol Somboonyosdes; Nuanjun Wichukchinda; Pathom Sawanpanyalert; Yijing He; Howard L McLeod; Wasun Chantratita
Journal:  J Hum Genet       Date:  2015-10-01       Impact factor: 3.172

2.  A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.

Authors:  Sherwin K B Sy; Jules Heuberger; Sireen Shilbayeh; Daniela J Conrado; Hartmut Derendorf
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

3.  The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Authors:  Patrick J Roberts; Kristan D Rollins; Angela D M Kashuba; Mary F Paine; Andrew C Nelsen; Eric E Williams; Cassandra Moran; Jatinder K Lamba; Erin G Schuetz; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-05-19       Impact factor: 3.922

Review 4.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

5.  The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome.

Authors:  Janet K Coller; Jeyamani Ramachandran; Libby John; Jonathan Tuke; Alan Wigg; Matthew Doogue
Journal:  Br J Clin Pharmacol       Date:  2019-07-24       Impact factor: 4.335

6.  Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.

Authors:  Joanne S L Lim; Xiang A Chen; Onkar Singh; Yoon S Yap; Raymond C H Ng; Nan S Wong; Mabel Wong; Edmund J D Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

7.  Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.

Authors:  Fabiana B Kohlrausch; Ángel Carracedo; Mara H Hutz
Journal:  Mol Biol Rep       Date:  2014-01-18       Impact factor: 2.316

8.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

9.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Authors:  M A Perera; R K Thirumaran; N J Cox; S Hanauer; S Das; C Brimer-Cline; V Lamba; E G Schuetz; M J Ratain; A Di Rienzo
Journal:  Pharmacogenomics J       Date:  2008-09-30       Impact factor: 3.550

10.  Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; George C Sakellaropoulos; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Int J Med Sci       Date:  2010-05-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.